WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 535003

CAS#: 166173-78-0

Description: Fallypride is a dopamine receptor antagonist.

Chemical Structure

CAS# 166173-78-0

Theoretical Analysis

MedKoo Cat#: 535003
Name: Fallypride
CAS#: 166173-78-0
Chemical Formula: C20H29FN2O3
Exact Mass: 364.2162
Molecular Weight: 364.4614
Elemental Analysis: C, 65.91; H, 8.02; F, 5.21; N, 7.69; O, 13.17

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Fallypride

IUPAC/Chemical Name: Benzamide, 5-(3-fluoropropyl)-2,3-dimethoxy-N-((1-(2-propenyl)-2-pyrrolidinyl)methyl)-, (S)-


InChi Code: InChI=1S/C20H29FN2O3/c1-4-10-23-11-6-8-16(23)14-22-20(24)17-12-15(7-5-9-21)13-18(25-2)19(17)26-3/h4,12-13,16H,1,5-11,14H2,2-3H3,(H,22,24)/t16-/m0/s1


Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 364.4614 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Huhtala T, Poutiainen P, Rytkönen J, Lehtimäki K, Parkkari T, Kasanen I, Airaksinen AJ, Koivula T, Sweeney P, Kontkanen O, Wityak J, Dominiquez C, Park LC. Improved synthesis of [18F] fallypride and characterization of a Huntington's disease mouse model, zQ175DN KI, using longitudinal PET imaging of D2/D3 receptors. EJNMMI Radiopharm Chem. 2019 Aug 5;4(1):20. doi: 10.1186/s41181-019-0071-6. PMID: 31659519; PMCID: PMC6682833.

2: Zhang X, Liu F, Knapp KA, Nickels ML, Manning HC, Bellan LM. A simple microfluidic platform for rapid and efficient production of the radiotracer [18F]fallypride. Lab Chip. 2018 May 1;18(9):1369-1377. doi: 10.1039/c8lc00167g. PMID: 29658049.

3: Stark AJ, Smith CT, Petersen KJ, Trujillo P, van Wouwe NC, Donahue MJ, Kessler RM, Deutch AY, Zald DH, Claassen DO. [18F]fallypride characterization of striatal and extrastriatal D2/3 receptors in Parkinson's disease. Neuroimage Clin. 2018 Feb 10;18:433-442. doi: 10.1016/j.nicl.2018.02.010. PMID: 29541577; PMCID: PMC5849871.

4: Vyas NS, Buchsbaum MS, Lehrer DS, Merrill BM, DeCastro A, Doninger NA, Christian BT, Mukherjee J. D2/D3 dopamine receptor binding with [F-18]fallypride correlates of executive function in medication-naïve patients with schizophrenia. Schizophr Res. 2018 Feb;192:442-456. doi: 10.1016/j.schres.2017.05.017. Epub 2017 May 31. PMID: 28576546.

5: Mann T, Kurth J, Hawlitschka A, Stenzel J, Lindner T, Polei S, Hohn A, Krause BJ, Wree A. [18F]fallypride-PET/CT Analysis of the Dopamine D₂/D₃ Receptor in the Hemiparkinsonian Rat Brain Following Intrastriatal Botulinum Neurotoxin A Injection. Molecules. 2018 Mar 6;23(3):587. doi: 10.3390/molecules23030587. PMID: 29509680; PMCID: PMC6017015.

6: Mukherjee J, Constantinescu CC, Hoang AT, Jerjian T, Majji D, Pan ML. Dopamine D3 receptor binding of (18)F-fallypride: Evaluation using in vitro and in vivo PET imaging studies. Synapse. 2015 Dec;69(12):577-91. doi: 10.1002/syn.21867. Epub 2015 Oct 15. PMID: 26422464; PMCID: PMC4624469.

7: Kaur J, Khararjian A, Coleman RA, Constantinescu CC, Pan ML, Mukherjee J. Spinal cord dopamine D2/D3 receptors: in vivo and ex vivo imaging in the rat using (18)F/(11)C-fallypride. Nucl Med Biol. 2014 Nov-Dec;41(10):841-7. doi: 10.1016/j.nucmedbio.2014.08.002. Epub 2014 Aug 8. PMID: 25199843; PMCID: PMC4192035.

8: Joo YH, Kim JH, Son YD, Kim HK, Shin YJ, Lee SY, Kim JH. The relationship between excitement symptom severity and extrastriatal dopamine D2/3 receptor availability in patients with schizophrenia: a high-resolution PET study with [18F]fallypride. Eur Arch Psychiatry Clin Neurosci. 2018 Sep;268(6):529-540. doi: 10.1007/s00406-017-0821-y. Epub 2017 Jun 16. PMID: 28623450.

9: Fa YH, Ni JQ, Wu XJ, Tan JQ, Wu YW. Evaluation of the early response and mechanism of treatment of Parkinson's disease with L-dopa using 18F-fallypride micro-positron emission tomography scanning. Exp Ther Med. 2016 Jan;11(1):101-109. doi: 10.3892/etm.2015.2900. Epub 2015 Nov 27. PMID: 26889225; PMCID: PMC4726873.

10: Garcia A, Mirbolooki MR, Constantinescu C, Pan ML, Sevrioukov E, Milne N, Wang PH, Lakey J, Chandy KG, Mukherjee J. 18F-Fallypride PET of pancreatic islets: in vitro and in vivo rodent studies. J Nucl Med. 2011 Jul;52(7):1125-32. doi: 10.2967/jnumed.111.088583. Epub 2011 Jun 16. PMID: 21680697.

11: Kim JH, Cumming P, Son YD, Kim HK, Joo YH, Kim JH. Altered connectivity between striatal and extrastriatal regions in patients with schizophrenia on maintenance antipsychotics: an [18 F]fallypride PET and functional MRI study. Synapse. 2018 Dec;72(12):e22064. doi: 10.1002/syn.22064. Epub 2018 Aug 24. PMID: 30063263.

12: Gao M, Wang M, Mock BH, Glick-Wilson BE, Yoder KK, Hutchins GD, Zheng QH. An improved synthesis of dopamine D2/D3 receptor radioligands [11C]fallypride and [18F]fallypride. Appl Radiat Isot. 2010 Jun;68(6):1079-86. doi: 10.1016/j.apradiso.2009.09.071. Epub 2010 Jan 25. PMID: 20167502.

13: Smith CT, Dang LC, Burgess LL, Perkins SF, San Juan MD, Smith DK, Cowan RL, Le NT, Kessler RM, Samanez-Larkin GR, Zald DH. Lack of consistent sex differences in D-amphetamine-induced dopamine release measured with [18F]fallypride PET. Psychopharmacology (Berl). 2019 Feb;236(2):581-590. doi: 10.1007/s00213-018-5083-5. Epub 2018 Oct 22. PMID: 30350220; PMCID: PMC6401232.

14: Fu X, Zhu W, Guo Z, Shu G, Cui F, Yang F, Zhang Y, Ren Y, Zhang X, Zhang X, Chen Z, Ling L, Huang X, Zhang J. 18F-fallypride PET-CT of dopamine D2/D3 receptors in patients with sporadic amyotrophic lateral sclerosis. J Neurol Sci. 2017 Jun 15;377:79-84. doi: 10.1016/j.jns.2017.03.013. Epub 2017 Mar 10. PMID: 28477714.

15: Vandehey NT, Moirano JM, Converse AK, Holden JE, Mukherjee J, Murali D, Nickles RJ, Davidson RJ, Schneider ML, Christian BT. High-affinity dopamine D2/D3 PET radioligands 18F-fallypride and 11C-FLB457: a comparison of kinetics in extrastriatal regions using a multiple-injection protocol. Version 2. J Cereb Blood Flow Metab. 2010 May;30(5):994-1007. doi: 10.1038/jcbfm.2009.270. Epub 2009 Dec 30. PMID: 20040928; PMCID: PMC2897717.

16: Peyronneau MA, Saba W, Goutal S, Kuhnast B, Dollé F, Bottlaender M, Valette H. [(18)F]Fallypride: metabolism studies and quantification of the radiotracer and its radiometabolites in plasma using a simple and rapid solid-phase extraction method. Nucl Med Biol. 2013 Oct;40(7):887-95. doi: 10.1016/j.nucmedbio.2013.06.003. Epub 2013 Jul 25. PMID: 23891202.

17: Rominger A, Mille E, Zhang S, Böning G, Förster S, Nowak S, Gildehaus FJ, Wängler B, Bartenstein P, Cumming P. Validation of the octamouse for simultaneous 18F-fallypride small-animal PET recordings from 8 mice. J Nucl Med. 2010 Oct;51(10):1576-83. doi: 10.2967/jnumed.110.078451. Epub 2010 Sep 16. PMID: 20847158.

18: Kim JH, Choe YS, Cumming P, Son YD, Kim HK, Joo YH, Kim JH. Relationship of self-transcendence traits with in vivo dopamine D2/3 receptor availability and functional connectivity: An [18 F]fallypride PET and fMRI study. Synapse. 2019 Nov;73(11):e22121. doi: 10.1002/syn.22121. Epub 2019 Jul 11. PMID: 31206840.

19: Slifstein M, Hwang DR, Huang Y, Guo N, Sudo Y, Narendran R, Talbot P, Laruelle M. In vivo affinity of [18F]fallypride for striatal and extrastriatal dopamine D2 receptors in nonhuman primates. Psychopharmacology (Berl). 2004 Sep;175(3):274-86. doi: 10.1007/s00213-004-1830-x. PMID: 15024551.

20: Leung K. (S)-N-((1-Allyl-2-pyrrolidinyl)methyl)-5-(3-[18F] fluoropropyl)-2-methoxybenzamide. 2006 Aug 3 [updated 2008 May 17]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. PMID: 20641474.